NCT04169711 is a Phase 1 clinical trial of ARO-HIF2 in Clear Cell Renal Cell Carcinoma, sponsored by Arrowhead Pharmaceuticals.

Who is sponsoring NCT04169711?

NCT04169711 is sponsored by Arrowhead Pharmaceuticals.

What drugs are being tested in NCT04169711?

Interventions in NCT04169711: ARO-HIF2.

What condition does NCT04169711 study?

NCT04169711 studies Clear Cell Renal Cell Carcinoma.

Is NCT04169711 still recruiting?

NCT04169711 is currently completed. Last updated 9 October 2025.

Last reviewed 2025-10-09 · How we verify

NCT04169711

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study of ARO-HIF2 in Patients With Advanced Clear Cell Renal Cell Carcinoma

Completed Phase 1 Last updated 9 October 2025

What this trial tests

Phase 1 trial testing ARO-HIF2 in Clear Cell Renal Cell Carcinoma in 26 participants. Completed in 22 July 2022.

Timeline

17 August 2020

Primary endpoint
24 January 2022

22 July 2022

Quick facts

Lead sponsor	Arrowhead Pharmaceuticals
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	26
Start date	17 August 2020
Primary completion	24 January 2022
Estimated completion	22 July 2022
Sites	5 locations across United States

Drugs / interventions tested

ARO-HIF2 — full drug profile →

Conditions studied

Clear Cell Renal Cell Carcinoma — all drugs for Clear Cell Renal Cell Carcinoma →

Sponsor

Arrowhead Pharmaceuticals — full company profile →

Who can join

18 and older, any sex, with Clear Cell Renal Cell Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the safety and efficacy of ARO-HIF2 injection (also referred to as ARO-HIF2) and to determine the recommended Phase 2 dose in the treatment of patients with advanced clear cell renal cell carcinoma (ccRCC).

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Therapeutic siRNA: state of the art.
Hu B, Zhong L, Weng Y, Peng L, et al · · 2020 · cited 991× · PMID 32561705 · DOI 10.1038/s41392-020-0207-x
Therapeutic siRNA: State-of-the-Art and Future Perspectives.
Friedrich M, Aigner A. · · 2022 · cited 256× · PMID 35997897 · DOI 10.1007/s40259-022-00549-3
The hypoxia-driven crosstalk between tumor and tumor-associated macrophages: mechanisms and clinical treatment strategies.
Bai R, Li Y, Jian L, Yang Y, et al · · 2022 · cited 200× · PMID 36071472 · DOI 10.1186/s12943-022-01645-2
Paving the Road for RNA Therapeutics.
Dammes N, Peer D. · · 2020 · cited 159× · PMID 32893005 · DOI 10.1016/j.tips.2020.08.004
Targeting hypoxia-inducible factors: therapeutic opportunities and challenges.
Yuan X, Ruan W, Bobrow B, Carmeliet P, et al · · 2024 · cited 144× · PMID 38123660 · DOI 10.1038/s41573-023-00848-6
Non-coding RNAs in human health and disease: potential function as biomarkers and therapeutic targets.
Loganathan T, Doss C GP. · · 2023 · cited 133× · PMID 36625940 · DOI 10.1007/s10142-022-00947-4
Recent Advances in Oligonucleotide Therapeutics in Oncology.
Xiong H, Veedu RN, Diermeier SD. · · 2021 · cited 132× · PMID 33804856 · DOI 10.3390/ijms22073295
Current Advances in RNA Therapeutics for Human Diseases.
Zogg H, Singh R, Ro S. · · 2022 · cited 117× · PMID 35269876 · DOI 10.3390/ijms23052736

Verify or expand the search:

Other recruiting trials for Clear Cell Renal Cell Carcinoma

Currently open trials in the same condition.

NCT06863311 — Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear C · Phase 2 · recruiting
NCT07227415 — Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Antica · Phase 1, PHASE2 · recruiting
NCT07187778 — Phase II Trial of Single Agent Belzutifan or Pembrolizumab Versus Combination as Neoadjuvant Therapy in Clear Cell Renal · Phase 2 · recruiting
NCT07389629 — Iparomlimab and Tuvonralimab (QL1706) Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC · Phase 2 · recruiting
NCT06805825 — A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Expres · Phase 1 · recruiting

Other Arrowhead Pharmaceuticals trials

Trials by the same sponsor.

NCT07037771 — A Phase 3 Study of Zodasiran in Adolescent and Adult Subjects With Homozygous Familial Hypercholesterolemia (YOSEMITE) · Phase 3 · recruiting
NCT05537025 — Study of ARO-MMP7 Inhalation Solution in Healthy Subjects and Patients With Idiopathic Pulmonary Fibrosis · Phase 1, PHASE2 · completed
NCT05533294 — Study of ARO-RAGE in Healthy Subjects · Phase 1 · completed
NCT05413135 — Study of ARO-APOC3 in Adults With Dyslipidemia · Phase 2 · completed
NCT05276570 — Study of ARO-RAGE in Healthy Subjects and Patients With Inflammatory Lung Disease · Phase 1, PHASE2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04169711 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Arrowhead Pharmaceuticals
Last refreshed: 9 October 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04169711.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing